Healthcare
Live Price
Offline$21.63
+4.54% today
1Y Change
+141.41%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prenetics Global Limited (PRE) is a Healthcare stock with a market cap of $240.00M and listed on NASDAQ. The stock last traded around $21.63 and up 141.4% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +201.7%, EPS growth of -14.0%, a dividend yield of 0.0%. What stands out right now is revenue +201.7%, EPS -14.0%, free cash flow +26.5% with operating margin -41.3% and ROIC -22.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRE Max Drawdown
-34.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.5M
-4.8% YoY
FY Net Income
-$174.0M
+8.6% YoY
Free Cash Flow
$2.0M
-75.5% YoY
Revenue Growth
+201.7%
EPS Growth
-14.0%
Gross Margin
53.0%
Net Margin
-61.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 92M | 31M | 22M | 13M | 13M |
| Gross Profit | 49M | 15M | 9M | 4M | 4M |
| Operating Income | -37M | -48M | -52M | -66M | -57M |
| EBITDA | -34M | -52M | -48M | -218M | -209M |
| Net Income | -58M | -46M | -63M | -190M | -174M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32M | 52M | 46M | 147M | 35M |
| Total Assets | 204M | 214M | 254M | 312M | 149M |
| Total Liabilities | 29M | 42M | 44M | 69M | 549M |
| Shareholder Equity | 175M | 170M | 206M | 237M | -401M |
| Total Debt | 2M | 6M | 2M | 7M | 492M |
| Net Debt | -30M | -46M | -43M | -140M | 456M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13M
-7.6% YoY
Capital Expenditures
11M
-79.9% YoY
Free Cash Flow
2M
-75.5% YoY
Key ratios
Gross Margin
53.0%
Operating Margin
-41.3%
Net Margin
-61.3%
ROE
-36.0%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.